Summary: In an open-label, single-centre randomized controlled trial of 180 adults with type 2 diabetes, an integrated cloud-hospital data platform combined with dietary management and individualized education videos lowered HbA1c at 12 weeks versus routine care (6.9 plus or minus 0.9% vs 7.4 plus or minus 0.7%, P less than 0.01). The headline 13.4% weight reduction was confined to overweight or obese platform-arm patients who were also taking semaglutide, not to the platform itself.
PICO Summary
| Element | Detail |
|---|---|
| Population | 180 adults with type 2 diabetes; prospective, single-centre randomized controlled trial (China). Subgroup of overweight or obese patients analysed for weight outcomes. |
| Intervention | Integrated cloud-hospital data platform with dietary management plus individualized diabetes education videos delivered through the platform (Group B). Some overweight or obese patients in this arm also received semaglutide. |
| Comparison | Routine standard diabetes care (Group A). |
| Outcome | Primary endpoints were change in HbA1c and body weight to Week 12. HbA1c was lower with the platform: 6.9 plus or minus 0.9% (Group B) vs 7.4 plus or minus 0.7% (Group A), P less than 0.01. Rates of fasting glucose below 7 mmol/L and HbA1c below 7% were higher in Group B. Significant weight and BMI reduction occurred in overweight or obese platform-arm patients; the 13.4% reduction at 12 weeks was specific to those also using semaglutide. Between-group 95% CIs, absolute risk reductions and NNT were not reported in the abstract. |
Integrated data platform plus dietary management
RCT · type 2 diabetes · 12 weeks
A cloud-hospital data platform with dietary management and education videos lowered HbA1c by about half a percentage point versus routine care at 12 weeks. The 13.4% weight loss was confined to overweight or obese patients also taking semaglutide.
Expert Commentary
This trial supports a modest verdict: a structured digital platform layered onto dietary management was associated with a lower HbA1c at 12 weeks than routine care, with a between-group difference of roughly half a percentage point that reached statistical significance. The signal is plausible and consistent with the broader literature on intensified, technology-supported self-management. It should not, however, be read as proof that the platform produces large metabolic gains. The most arresting figure, a 13.4% weight reduction, was generated by overweight or obese participants who were additionally taking semaglutide, so that effect is largely attributable to a potent pharmacological agent rather than to the data platform, and conflating the two would overstate the technology. The principal limitation is design: an education-and-platform intervention cannot be blinded, so the open-label structure leaves performance and ascertainment bias unaddressed, and the single-centre setting with a 12-week horizon limits durability and generalisability. No between-group confidence intervals, absolute risk reductions, or numbers needed to treat were reported, which constrains clinical interpretation. Can I use this with my patients? Cautiously yes, for motivated adults with type 2 diabetes who can engage with a structured digital programme as an adjunct to standard care, but not as a substitute for proven pharmacotherapy. I would welcome a larger, multi-centre trial with longer follow-up that separates the platform effect from any concurrent glucose-lowering or weight-lowering drugs.
References
Liu X, Wang X, Xie M, Cao L. Application of the integrated data platform combined with dietary management for adults with diabetes: a prospective randomized controlled trial. J Diabetes Investig. 2024;15(11):1548-1555. doi:10.1111/jdi.14296